Bio + Health

Investing in Hippocratic AI

Julie Yoo and Justin Larkin Posted May 16, 2023

“Solving consumer engagement is worth $1 trillion to our organization,” said a health plan executive to me one day. He was obviously being a bit sensationalist with the magnitude of the number, but it’s been a common thread in strategic dialogue across all of healthcare for quite a while—that so much of the high cost, waste, and poor clinical outcomes from which our healthcare system suffers stems from the lack of individuals’ engagement with it—or the flip, which is healthcare organizations’ inability to engage, at scale and cost-effectively, with its patients and members.

And it’s not just consumer engagement that needs to be solved—our country’s severe clinician burnout problem, combined with overall high rates of staff churn, are causing healthcare organizations to falter at delivering on their core services. One study shows that the average hospital has turned over 100.5% of its workforce in the last 5 years!

In this context, when it comes to generative AI, healthcare is an industry that we view as holding the most potential for tangible and measurable impact. Closing the gap on a shortage of millions of healthcare workers in the next several years, while also trying to increase leverage for those already in the workforce, requires much more than just the traditional paths of training or importing more human labor. We’re excited to be backing Hippocratic AI as they apply generative AI to execute against this opportunity set.

Imagine a world in which every patient, provider, and administrative staff member could interact with an immediately available, fully context-aware, completely capable, and charismatic conversationalist to help each individual pick the right path or do their job better (a form of “always-on triage,” as we’ve described in the past). Imagine that the marginal cost of engaging a patient through empathetic phone calls was on the order of $0.10 per hour, as opposed to the $50+ it might cost today. The very nature of generative AI—conversational, scalable, accessible to non-technical users—has the potential to solve the shortcomings of previous generations of rules-based chatbots and other such products in making these concepts a reality.

But AI applications in healthcare also pose among the highest stakes of any industry. AI skeptics might point to the lack of focus on responsibility, safety, and regulatory compliance exhibited by many companies in this space. Not to mention the challenge of assembling a cross-disciplinary team with deep expertise in LLM development, healthcare delivery, and healthcare administration to build AI products that actually work.

Hippocratic AI’s name alone represents their safety-first ethos (referring to the Hippocratic Oath that physicians commit to, in which the core principles are to “do no harm” to patients and to maintain confidentiality of a patient’s medical information). They’ve built a unique framework to incorporate professional-grade certification, RLHF (reinforcement learning from human feedback) through a panel of healthcare professionals, and “bedside manner” into their non-diagnostic, patient-facing conversational LLMs, with the recognition that passing a medical board exam is not enough to ensure that a model is ready to be deployed into a real-world setting.

We’ve known the CEO, Munjal Shah, since investing in his last company in 2017 (which was his third, after previously selling an AI company to Google), and thus know he has uniquely earned secrets about how to build a company at the intersection of AI and healthcare. He most recently ran a Medicare brokerage business that involved a national-scale call center that made personalized recommendations to seniors based on their individual claims history. There, he led through the operational pains of scaling an empathetic but efficient engagement platform for consumers in a regulated healthcare context. We believe these competencies give him and his founding team (composed of individuals with clinical, LLM development, and healthcare operations experience) an edge in understanding what it takes to bring high-impact, responsible, and safe generative AI products to market, and consider it a privilege to be backing him again.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Infra

new Investing in Deeptune

Marco Mascorro and Martin Casado
Growth

new Investing in Mind Robotics

Sarah Wang
Growth

Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Bio + Health

Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.